EGFR and non-small cell lung carcinoma: Deng et al. conducted a small prospective single–center study to explore the role of ctDNA in detecting EGFR mutations in the plasma of patients with suspected advanced NSCLC but without a pathologic diagnosis and to evaluate the efficacy of first-generation EGFR TKIs in the first-line setting [53].